<PAGE>

                                                                    Exhibit 10.3

                                LICENSE AGREEMENT
                                   as amended
      September 30, 1997, March 11, 1998, August 10, 1998 & August 25, 1998

          THIS LICENSE AGREEMENT is made and entered into as of the 30th day of
July 1997, by and between IRVINE SENSORS CORPORATION, a Delaware Corporation
(the "Company"), and ADVANCED TECHNOLOGY PRODUCTS, LLC, a California limited
liability company ("ATP"), with reference to the following facts:

               A. The Company is the owner of certain intellectual property
               rights (the "Technology") to two high technology products, the
               Real Time Vector Image Processor ("VIP-20") and Electronic Film
               ("E-Film"). The Technology is described in Exhibit A annexed
               hereto.

               B. ATP desires to obtain the Technology for $400,000 and to
               license the Technology back to the Company to develop the VIP-20
               and E-Film into commercially marketable products.

               C. The parties desire to enter into this Agreement to define
               their future rights to the Technology.

          NOW, THEREFORE, for good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, the parties hereto do hereby agree as
follows:

     1. Purchase of Technology. ATP hereby agrees to purchase the Technology
from the Company for the sum of Four Hundred Thousand Dollars ($400,000). The
parties shall use their best efforts to consummate the sale of the Technology by
December 31, 1997.

     2. License. ATP hereby grants to the Company and the Company accepts a
transferable, exclusive, worldwide license to use the Technology for the purpose
of developing and manufacturing products utilizing the Technology ("Licensed
Products"), to enter into and perform contracts that utilize the Technology with
any party, and to use, sell or otherwise dispose of Licensed Products in all
countries of the world.

     3. Product Development Funding. ATP shall have the right, but not the
obligation, to fund the research and development and manufacturing and marketing
activities to be carried out by the Company, in an amount not to exceed
$1,100,000. If ATP commences to fund such activities it shall have the right to
suspend such funding in its sole discretion.

     4. Royalties.

          4.1 In consideration of the license granted in Section 2 hereof and
its commitment to fund certain activities relating to the Products pursuant to
Section 3 hereof, the Company agrees that its direct sales of Licensed Products
covered by one or more claims of any of the patents or Technology listed in
Exhibit A shall be subject to royalty payments on the Gross Selling Price
thereof (as hereinafter defined). Such royalty shall be paid at the following
rates, subject to the election of investors in ATP's offering of limited
liability company interests (the "Offering"):

<PAGE>

               a. Royalty Program "A". This section deleted in its entirety.

               b. Royalty Program "B". For investors not electing the Share
redemption option provided for in Section 5.2, royalties will be paid at the
following rates for each $100,000 contributed by ATP on behalf of such investors
to the Company pursuant to Sections 1 and 3 hereof: (i) 1% of the Gross Selling
Price of Licensed Products for each $100,000 invested in the Company until
distributions equal $300,000 per $100,000 invested, thereafter (ii) 1/3% of the
Gross Selling Price of Licensed Products for each $100,000 invested in the
Company until distributions equal $1,000,000 per $100,000 invested, thereafter
(iii) 1/10% of the Gross Selling Price of Licensed Products for each $100,000
invested in the Company for the life of the Licensed Products. The parties
acknowledge that for purposes of calculating royalties due under this section
that the amount of capital invested by ATP in the Company is deemed to be
$200,000.

               c. Royalty Program "C". For investors who have previously elected
Royalty Program "A" or "B" as set forth above, these investors may now elect by
September 30, 1998 to participate in Royalty Program "C" and end their
participation in Royalty Program "A" or "B". Investors previously electing
Royalty Program "A" have the option of: (a) exchanging their interest in E-Film
product royalties for shares of common stock ("Shares") in IMAGEK, Inc., a
wholly owned subsidiary of Irvine Sensors Corporation at the exchange rate of
8,500 Shares per $10,000 invested in the Company (IMAGEK has reserved
approximately 11.3% of its initial capital structure to effectuate this offer to
the Company); (b) retaining their VIP 20 product royalties, but agreeing that
such VIP 20 product royalties shall end when the sum of those royalties and the
public market value of their IMAGEK, Inc. common stock received pursuant to (a)
above equals three (3) times their initial investment in the Company; and (c)
retaining 50% of their share redemption rights as granted in Section 5.2 of the
Licensing Agreement. Investors previously electing Royalty Program "B" have the
option of: (a) exchanging their interest in E-Film product royalties for shares
of common stock ("Shares") in IMAGEK, Inc. a wholly owned subsidiary of Irvine
Sensors Corporation at the exchange rate of 8,500 Shares per $10,000 invested in
the Company (IMAGEK has reserved approximately 11.3% of its initial capital
structure to effectuate this offer to the Company); and (b) retaining their VIP
20 product royalties, but agreeing that such VIP 20 product royalties shall end
when the sum of those royalties and the public market value of their IMAGEK,
Inc. common stock received pursuant to (a) above equals ten (10) times their
initial investment in the Company. The parties acknowledge that all investors in
this classification have elected to have their E-Film royalty rights converted
to shares of common stock of IMAGEK, but shall continue to be entitled to
receive royalty payments for VIP 20 sales as stated in the Third Amendment to
the License Agreement.

          4.2 The expression "Gross Selling Price" shall for the purpose of this
Agreement mean the invoice price for Licensed Products sold by the Company
during the term of this Agreement, such price not to include normal discounts
actually granted, insurance fees and packing and transportation charges as
invoiced separately to customers, and duties and sales taxes actually incurred
and paid by the Company in connection with delivery of such Licensed Products.

          4.3 Within thirty (30) days after the close of each fiscal quarter of
the Company of each year during which this Agreement shall be in force, the
Company hereby undertakes to submit to ATP a statement in writing duly certified
by an officer of the Company, setting forth with respect to the Company for the
quarterly period concerned:

          a)   the Gross Selling Price of royalty-bearing Licensed Products sold
               by the Company;

          b)   the royalties and other license fees received by the Company from

<PAGE>

               its sublicensees; and

          c)   the royalty accrued to ATP.

Payment of the above-described royalties shall be made within thirty (30) days
after the end of each fiscal quarter of the Company.

     5. Reversion of Technology to the Company/Share Redemption Provision

          5.1 At such time as the Company has paid to ATP 315% of the gross
capital contributions contributed by ATP to the Company all of ATP's right,
title and interest in and to the Technology shall forthwith be transferred to
the Company, without any further action on the part of ATP or the Company. This
Agreement shall not terminate, however, and the Company's obligation to pay
royalties to ATP pursuant to Section 4.1 shall continue if there were any
investors in the Offering electing Royalty Program "B." If there were none then
this Agreement shall thereupon terminate.

          5.2 Each ATP investor electing Royalty Program "A" as set forth in
Section 4.1 above shall have the right to cause the Company to redeem such
contributions by giving notice to ATP within five years after such contribution
date, but prior to such investor receiving an amount of distributions equal to
100% of said capital contributions. Such redemption shall be in the form of
restricted shares of common stock of ISC to be issued at the greater of: (a) the
discounted rate of 20% less than the market price of the Company's common stock
at the time of redemption, or (b) $1.00 per share, for each dollar invested.
Notwithstanding the foregoing, if such shares of common stock of ISC issued
pursuant to this redemption provision are "registered" and "free trading" then
they shall be issued at the market price of the Company with no discount. (For
example, if the Company's common stock were trading at $2.00 per share at the
time of redemption then the conversion price, assuming the shares to be issued
were "restricted" and not "free trading," would be $1.60 per share; however, if
the common stock were trading at $.875 at the time of redemption, then the
conversion price would be $1.00). Such redemption provision shall automatically
be triggered if any termination event pursuant to section 8.1(b) herein shall
occur. Any such capital contributions redeemed pursuant to this section shall
reduce, dollar for dollar, the amount of the Company's obligation set forth in
section 5.1 herein. Royalty Program "A" investors who have elected Royalty
Program "C" shall retain 50% of their share redemption rights as granted in this
Section of the Licensing Agreement.

     6. Term of Agreement.

          6.1 Unless terminated earlier in accordance with the provisions of
section 5 or section 9 hereof, this Agreement shall continue in force and effect
until June 30, 2025.

          6.2 In the event that this Agreement is terminated in accordance with
section 9 hereof, all rights of the Company under this Agreement shall
terminate, but the accrued obligations of the Company set forth in section 2
shall continue.

     7. Warranties of ATP and the Company.

          7.1 ATP represents and warrants to the Company that it has legal power
to enter into this Agreement and to extend the rights granted to the Company in
this Agreement, that subject to payment of the purchase price as set forth in
section 1 hereof, it owns the Technology and has the right to transfer the same
to the Company, and that it has not made any commitments to others inconsistent
with or in derogation of such rights. ATP makes no representations, extends no
warranty of any kind, either

<PAGE>

expressed or implied, and assumes no responsibilities whatever with respect to
the adequacy, accuracy or utility of any information obtained by the Company
under this Agreement; and ATP assumes no responsibilities whatever with respect
to use by the Company or any third party of any information obtained by the
Company under this Agreement or with respect to any use, sale or other
disposition by the Company or its vendees or other transferees of any Licensed
Products.

          7.2 The Company represents and warrants to ATP that it will use its
best efforts to perform all reasonable and customary research and development
activities necessary to bring the Products to market. The Company further
represents and warrants to ATP that it will use its best efforts to manufacture
and market the Products either directly or through third parties.

          7.3 The Company represents and warrants to ATP that it is not
presently subject to an material pending or threatened litigation that could
affect its ability to perform under this Agreement.

          7.4 Nothing contained in this Agreement shall be construed as a
warranty or representation that the Company will be able to successfully
manufacture, sell or use any Licensed Products or that the manufacture, sale,
use or other disposition of Licensed Products hereunder will be free from
infringement of patents, utility models, copyrights, trademarks and/or design
patents of third parties.

     8. Sublicenses.

          8.1 The Company shall have the right, throughout the term of this
Agreement, to enter into sublicense agreements with third parties for the use of
the Technology. The Company agrees to negotiate all such sublicense agreements
at arms/ length and in good faith, so as to maximize the return to it under each
such sublicense agreement, and, in turn, the return to ATP under this Agreement.

          8.2 In the event of the valid termination of the Company's license
under this Agreement for any reason, any existing sublicensee shall have the
option for 90 days from the date of notice of termination by ATP to covert to a
direct license from ATP on comparable terms as contained herein, as nearly as
may be practicable.

          8.3 The Company agrees to give ATP (i) notice of any agreement in
principle to enter into any such sublicense, within 10 days of the date of said
agreement, and (ii) a copy of the fully executed agreement promptly upon
execution thereof.

          8.4 ATP shall give notice promptly to every sublicensee of any notice
of default sent to the Company hereunder, to enable such sublicensee to utilize
the option provided for in section 8.2. above.

     9. Termination.

          9.1 Notwithstanding the provisions of section 4 hereof, this Agreement
may be terminated:

               a) by ATP giving notice by registered mail or telegram to the
Company in the event of the Company being in breach of or in default under any
duty or obligation of this Agreement and the Company having failed to remedy
such breach or default within thirty (30) days of ATP having served written
notice to remedy such breach or default, with the date of service deemed to be
the date of mailing or the date of the telegram; or

               b) by ATP upon written or telegraphic notice to the Company in
the event of (i) the bankruptcy of ISC, (ii) cessation of operations by ISC,
(iii) the seizure or attachment of all or a

<PAGE>

substantial part of ISC's assets, or (iv) the termination of ISC's research and
development or manufacturing and marketing activities relating to the Products.
In any of the foregoing events ATP shall also have the right to elect to not
terminate this Agreement, but to treat the Company as a non-exclusive licensee
and ATP will be entitled to contract with other third parties to further develop
and market the Products.

          9.2 In the event that a dispute shall arise as to the validity of any
notice of default sent by ATP to the Company hereunder, the parties agree to
submit the same to arbitration in Orange County, California, in accordance with
the then current rules of the American Arbitration Association.

     10. Waiver/Severability.

          10.1 The waiver by either party of a breach or default in any of the
provisions of this Agreement by the other party shall not be construed as a
waiver by such party of any succeeding breach of the same or other provisions
nor shall any delay or omission on the part of either party to exercise or avail
itself of any right, power or privilege that it has or may have hereunder
operate as a waiver of any right, power or privilege by such party.

          10.2 If any term, clause or provision of this Agreement shall be
judged to be invalid, the validity of any other term, clause or provision shall
not be thereby affected and such invalid term, clause or provision shall be
deemed deleted from this Agreement.

     11. Applicable Law. This Agreement shall be governed by and construed, and
any claim or controversy arising with respect thereto shall be determined, in
accordance with the laws and in the competent courts of the State of California.

     12. Miscellaneous.

          12.1 This Agreement embodies the entire understanding of the parties
as it relates to their respective rights in and to the Technology, and this
Agreement supersedes any prior agreement or understanding between the parties
with respect to such subject matter. No amendment or modification of this
Agreement shall be valid or binding upon the parties unless signed by their
respective, duly authorized, officers.

          12.2 Nothing contained in this Agreement shall be construed as
conferring by implication, estoppel or otherwise upon either party hereunder any
license or other right expect the licenses and rights expressly granted
hereunder to a party hereto.

          12.3 This Agreement cannot be assigned by any party without the
written consent of the other party hereto and should any assignment be made by
the one party without the written consent of the other party such assignment
will be null and void. ATP does hereby consent to the assignment of certain
rights of the Company to IMAGEK as contained in the Technology Transfer
Agreement dated August 25, 1998.

          12.4 Any notice or statement hereunder shall be deemed to be
sufficiently given or rendered when sent by registered mail, postage prepaid,
and if given or rendered to ATP, addressed to:

<PAGE>

          Advanced Technology Products, LLC
          3001 Redhill Avenue
          Building III, Suite 208
          Costa Mesa, CA  92626
          Attn: John C. Carson

or, if given or rendered to the Company, addressed to:

          Irvine Sensors Corporation
          3001 Redhill Avenue
          Costa Mesa, CA  92626
          Attn: James D. Evert, President

or in any case to such changed address or person as ATP or the Company shall
have specified to the other by written notice.

     IN WITNESS WHEREOF, the parties hereof have caused this Agreement to be
signed as of the date first above written.

IRVINE SENSORS CORPORATION
a Delaware corporation


By: /s/ James D. Evert
    -------------------------
    James D. Evert, President


ADVANCED TECHNOLOGY PRODUCTS, LLC
a California limited liability company


By: /s/ John C. Carson
    --------------------------------
    John C. Carson, Managing Member

<PAGE>

                         EXHIBIT A TO LICENSE AGREEMENT

For purposes of establishing the Company's rights, "Technology" shall be defined
as any and all technology conceived and/or developed by the Company for the
Products defined as "VIP-20" and "Electronic Film" in ATP's Private Placement
Memorandum dated August 1, 1997, including any technology covered by any of the
U.S. Patents secured by the Company through applications made on behalf of the
Products.